New urine test detects 95% of bladder cancer cases in study: What patients should know

A new urine test that analyzes tiny genetic molecules, called RNA, in urine has the potential to detect bladder cancer in 95 percent of cases, including early stages, according to a study published in Nature Medicine on October 2, 2026. Unlike traditional liquid biopsy tests that focus on DNA released by tumors into the blood, this technique targets RNA, which carries information about cell activity and gene expression.

Urine serves as a direct sample from the bladder, allowing it to carry molecular clues released by cancer cells. The test could potentially offer a non-invasive way to identify bladder cancer and provide information about the tumor type and recurrence risk. Dr. Sheeba Santhmayer, a consultant radiation oncologist, explains that the test works by analyzing cell-free RNA molecules present in urine, revealing changes in patterns associated with bladder cancer.

While a sensitivity of 95 percent is promising, indicating the test detected 95 out of 100 bladder cancer cases in the study, it does not guarantee the test's overall accuracy or its ability to rule out cancer. Researchers are also investigating the possibility of using this technique to detect other cancers, such as kidney and prostate cancers, through urine analysis.

However, the technology is still in its early stages and requires further clinical validation before it can be considered a routine diagnostic tool.